GHK-Cu and copper peptides: what the skin and hair evidence shows

Copper peptides are in serums everywhere. Here is what has been shown in people, what is still lab work, and why topical and injected use are very different questions.

Copper peptides are one of the most common "active" ingredients in skin and scalp products. They also show up as injectable research vials, often with big promises attached. The evidence behind those two uses is not the same, and it helps to separate them.

This post looks at GHK-Cu, the best-studied copper peptide, and its lesser-known relative AHK-Cu.

What GHK-Cu is

GHK is a tiny peptide made of three amino acids: glycine, histidine and lysine. It occurs naturally in human blood plasma, saliva and urine, and it binds tightly to copper. The copper-bound form is GHK-Cu, also sold as "copper tripeptide-1."

Levels fall with age. One review by Loren Pickart, the researcher who first described GHK, puts plasma levels at about 200 ng/mL at age 20 and about 80 ng/mL by age 60. That decline is part of why it attracted interest as an anti-aging ingredient, though a falling level does not by itself prove that adding more back does anything.

What it does in the lab

In cell and animal studies, GHK-Cu has been reported to:

increase production of collagen, elastin and glycosaminoglycans (the building blocks of skin's support structure)
support wound healing and the growth of new blood vessels and nerves
act as an antioxidant and calm inflammation
shift the activity of many genes, based on gene-expression database studies

These findings are real, but they come from dishes of cells, animal wounds and computer analysis of gene data. They show what the molecule can do under controlled conditions, not what a serum or an injection does in a person.

What has been shown in people

The human evidence is almost all topical and cosmetic. Reviews by Pickart and colleagues summarize several small studies from the late 1990s and 2000s:

Collagen in skin. In a study of women around age 50, a GHK-Cu cream applied to the thigh for one month increased collagen in 70% of participants, compared with 50% for a vitamin C cream and 40% for retinoic acid.
Facial photoaging. A 12-week study in 71 women with sun-damaged skin reported fewer fine lines, better firmness and improved skin density.
Eye area. A 12-week study of 41 women found a GHK-Cu eye cream reduced lines and wrinkles more than placebo or a vitamin K cream.
Skin thickness. A 12-week study in 67 women aged 50 to 59 found increased growth of skin cells on biopsy.

A few caveats are worth knowing. These studies are small, several were presented at meetings or in trade journals rather than major peer-reviewed journals, and many were connected to companies making the products. They are encouraging, but they are not the kind of large, independent, placebo-controlled trials that back prescription skin treatments such as tretinoin.

What about hair?

GHK-Cu is often marketed for hair growth. Review articles list "increased hair growth and thickness" and "larger follicles" among its effects, but the supporting data is thin and mostly preclinical. We could not find a solid, controlled human trial showing GHK-Cu regrows hair on its own.

This is where AHK-Cu comes in.

AHK-Cu: the hair-focused cousin

AHK-Cu (alanine, histidine, lysine plus copper, sometimes called "copper tripeptide-3") is chemically close to GHK-Cu. Its research base is very small. The main study, published in 2007, found that AHK-Cu lengthened isolated human hair follicles in culture and helped dermal papilla cells (the cells that drive hair growth) multiply and survive.

That is a lab result on follicles removed from the body. There are almost no published human trials of AHK-Cu. Products that combine it with GHK-Cu are relying mostly on that early lab work and on user reports.

Topical versus injected

This is the biggest gap in the copper peptide story.

Topical use is where the human data lives. Copper peptides have been used in cosmetics for decades. Cosmetics are not drugs, so they are not FDA-approved for any effect, but the ingredient has a long track record in creams and serums.

Injected use is a different matter. There is very little published human data on injecting GHK-Cu or AHK-Cu, and claims about whole-body "anti-aging" effects are extrapolated from lab and topical work. The FDA lists injectable GHK-Cu among bulk substances that may present significant safety risks when compounded. It cites possible immune reactions from clumping (aggregation) and peptide impurities, and limited human safety data. The FDA has said it plans to take GHK-Cu to its compounding advisory committee by the end of February 2027.

Copper itself is another consideration. People with Wilson's disease or other copper-handling disorders face particular concerns, and the long-term effects of repeated copper peptide injections have not been studied.

How to read the claims

A useful rule when you see a copper peptide product:

Skin firmness and fine lines, applied to skin: small human studies, modest effects.
Hair growth: mostly lab and follicle-culture data; human evidence is weak.
Wound healing: strong in animals, limited in people.
Injected, whole-body effects: largely untested in humans.

If you want to compare entries side by side, see the GHK-Cu and AHK-Cu pages, which list each claim by evidence type.

This is educational information, not medical advice.